Drugs / arvenacogene sanparvovec
arvenacogene sanparvovec
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06120582 | May 2023 → Nov 2025 overdue | hemophilia B | Biocad | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06700096 | Nov 2024 → Apr 2027 expected | hemophilia B | Biocad | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arvenacogene sanparvovec | “After completion of lead-in period subjects will enter the main period which starts with ANB-002 (arvenacogene sanparvovec) infusion.” NCT06700096 ↗ |
| Known as | ANB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06120582 ↗ |
| Known as | Arvenacogen sanparvovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068206 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated viral vector” NCT06120582 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT06120582 ↗ |